Cite
HARVARD Citation
Hsu, J. et al. (2021). Pharmacometric analyses of alectinib to facilitate approval of the optimal dose for the first‐line treatment of anaplastic lymphoma kinase–positive non‐small cell lung cancer. CPT: pharmacometrics & systems pharmacology. pp. 1357-1370. [Online].